Jonathan Couchman - Aug 13, 2021 Form 4 Insider Report for ENZON PHARMACEUTICALS, INC. (ENZN)

Role
10%+ Owner
Signature
/s/ Jonathan Couchman
Stock symbol
ENZN
Transactions as of
Aug 13, 2021
Transactions value $
-$41,904
Form type
4
Date filed
8/17/2021, 06:07 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENZN Common Stock, $0.01 par value Sale -$19.5K -50K -12.5% $0.39 350K Aug 13, 2021 By Couchman Family Fund F1, F3, F6
transaction ENZN Common Stock, $0.01 par value Sale -$22.4K -57.5K -2.74% $0.39 2.04M Aug 13, 2021 By Xstelos Corp. F1, F4, F6
holding ENZN Common Stock, $0.01 par value 4.72M Aug 13, 2021 By Jonathan Couchman F1, F2
holding ENZN Common Stock, $0.01 par value 633K Aug 13, 2021 By Myrexis, Inc. F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Form 4 is filed jointly by Jonathan Couchman ("Mr. Couchman"), Couchman Family Fund (the "Foundation"), Xstelos Corp. ("Xstelos") and Myrexis, Inc. ("Myrexis") (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock (the "Shares"). Each of the Reporting Persons expressly disclaims beneficial ownership of the Shares reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such Shares for purposes of Section 16 or for any other purpose.
F2 Represents shares owned directly by Mr. Couchman. As the sole trustee of the Foundation, Mr. Couchman may be deemed to beneficially own the Shares owned by the Foundation. As the Chief Executive Officer of Xstelos, Mr. Couchman may be deemed to beneficially own the shares of Common Stock owned by Xstelos. As the Chief Executive Officer of Myrexis, Mr. Couchman may be deemed to beneficially own Shares of Common Stock owned by Myrexis.
F3 Represents Shares owned directly by the Foundation. Mr. Couchman is the sole trustee of the Foundation. By virtue of this relationship, Mr. Couchman may be deemed to beneficially own the Shares owned directly by the Foundation, however he has no pecuniary interest in such Shares.
F4 Represents Shares owned directly by Xstelos. Mr. Couchman is the controlling shareholder and Chief Executive Officer of Xstelos. By virtue of these relationships, Mr. Couchman may be deemed to beneficially own the Shares owned directly by Xstelos. Mr. Couchman expressly disclaims beneficial ownership of such Shares except to the extent of his pecuniary interest therein.
F5 Represents Shares owned directly by Myrexis. Mr. Couchman is Chief Executive Officer of Myrexis. By virtue of this relationship, Mr. Couchman may be deemed to beneficially own the Shares owned directly by Myrexis. Mr. Couchman expressly disclaims beneficial ownership of such Shares except to the extent of his pecuniary interest therein.
F6 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions and the reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commision, upon request, full information regarding the number of shares purchased at each separate price.

Remarks:

Effective September 17, 2020, Michael Pearce, Brian Harper and Harper Asset Management, LLC ceased to be members of the Section 13(d) group and ceased to be Reporting Persons.